biotech

Viking Therapeutics' VK2735 targets the $100+ billion weight-loss market. Success could drive massive stock appreciation, but clinical and competitive risks remain substantial.

Ardelyx CEO sells $243K in shares via routine trading plan as company improves operationally; analysts see 170% upside potential.

$VEEV tumbles 37% but fortress market position, AI investments, and $20B TAM suggest attractive risk-reward at 20x forward earnings.

ORIC Pharmaceuticals surged then crashed 25% after-hours despite publishing positive Phase 1b trial results for cancer therapy candidate rinzimetostat, highlighting biotech market skepticism.

Agios Pharmaceuticals surges on FDA accelerated approval for mitapivat sickle cell treatment, enabling faster path to full approval despite company's ongoing losses.

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.

Biogen acquires Apellis Pharmaceuticals for $5.6 billion in cash, gaining two FDA-approved therapies with $689M in 2025 projected sales and mid-to-high teens growth expectations.

Sionna CLO liquidated 10,250 shares for $347k via pre-scheduled plan while retaining 50,935 options. Dual clinical trials expected mid-2026 with $310.3M cash runway through 2028.

Alvotech files 2025 Annual Report on Form 20-F with SEC, providing comprehensive financial disclosures to U.S. investors via SEC Edgar and company website.

Alvotech files 2025 Form 20-F, revealing operations across six continents as the Icelandic biosimilar developer pursues international market expansion.

$BIOG rallies as FDA approves high-dose Spinraza for spinal muscular atrophy, while litifilimab shows positive Phase 2 lupus results.

Corcept Therapeutics stock surged 9% following FDA approval of cancer drug Lifyorli. An analyst upgraded the stock to hold amid concerns about existing Korlym franchise performance.

Ligand Pharmaceuticals CFO Octavio Espinoza sold $688K in stock under a prearranged plan. The sale reflects portfolio diversification, not concerns, as the biotech firm posts strong 2025 results.

Xenon Pharmaceuticals' CMO sold $78K in shares via routine vesting, as stock surges 55% following positive Phase 3 trial results and $750M capital raise.

Novartis acquires Excellergy for up to $2 billion to develop Exl-111, a next-generation anti-IgE allergy drug in Phase 1 trials, strengthening its immunology pipeline.

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.

Novartis to acquire private biotech Excellergy for up to $2B, adding next-generation anti-IgE antibody Exl-111 targeting food allergy, chronic urticaria, and allergic asthma.

Celcuity stock rises over 4% after beating loss expectations and securing $166M cash position, with phase 3 trial results anticipated in Q2.

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.

Palvella COO sells ~$508K in shares via pre-planned trading arrangement amid 340% annual surge, driven by strong Phase 3 QTORIN rapamycin data and upcoming NDA submission.